Cargando…

Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolones

BACKGROUND: The ongoing global malaria eradication campaign requires development of potent, safe, and cost-effective drugs lacking cross-resistance with existing chemotherapies. One critical step in drug development is selecting a suitable clinical candidate from late leads. The process used to sele...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yizhe, Zhu, Fangyi, Hammill, Jared, Holbrook, Gloria, Yang, Lei, Freeman, Burgess, White, Karen L., Shackleford, David M., O’Loughlin, Kathleen G., Charman, Susan A., Mirsalis, Jon C., Guy, R. Kiplin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893776/ https://www.ncbi.nlm.nih.gov/pubmed/33608015 http://dx.doi.org/10.1186/s12936-021-03617-1

Ejemplares similares

Plasmid-free CRISPR/Cas9 genome editing in Plasmodium falciparum confirms mutations conferring resistance to the dihydroisoquinolone clinical candidate SJ733
por: Crawford, Emily D., et al.
Publicado: (2017)

Improvement of Oral Bioavailability of Pyrazolo-Pyridone Inhibitors of the Interaction of DCN1/2 and UBE2M
por: Kim, Ho Shin, et al.
Publicado: (2021)

Enantioselective palladium(0)-catalyzed intramolecular cyclopropane functionalization: access to dihydroquinolones, dihydroisoquinolones and the BMS-791325 ring system
por: Pedroni, J., et al.
Publicado: (2015)

Catalytic, selective, and stereocontrolled construction of C4 quaternary and homobenzylic dihydroisoquinolones by sp(3) C–H benzylation
por: Beng, Timothy K., et al.
Publicado: (2020)

Discovery of novel, orally bioavailable, antileishmanial compounds using phenotypic screening
por: Ortiz, Diana, et al.
Publicado: (2017)

Ligand design for Rh(iii)-catalyzed C–H activation: an unsymmetrical cyclopentadienyl group enables a regioselective synthesis of dihydroisoquinolones
por: Hyster, Todd K., et al.
Publicado: (2015)

Correction: Ligand design for Rh(iii)-catalyzed C–H activation: an unsymmetrical cyclopentadienyl group enables a regioselective synthesis of dihydroisoquinolones
por: Hyster, Todd K., et al.
Publicado: (2017)

Correction: Ligand design for Rh(iii)-catalyzed C–H activation: an unsymmetrical cyclopentadienyl group enables a regioselective synthesis of dihydroisoquinolones
por: Hyster, Todd K., et al.
Publicado: (2018)

MalVac: Database of malarial vaccine candidates
por: Chaudhuri, Rupanjali, et al.
Publicado: (2008)

Repositioning: the fast track to new anti-malarial medicines?
por: Lotharius, Julie, et al.
Publicado: (2014)

Malarial Pneumonia. Is There Such a Thing?
por: Burgess, J. Hay
Publicado: (1907)

Pharmacokinetics and Efficacy of the Spleen Tyrosine Kinase Inhibitor R406 after Ocular Delivery for Retinoblastoma
por: Pritchard, Eleanor M., et al.
Publicado: (2014)

An in vitro toolbox to accelerate anti-malarial drug discovery and development
por: Charman, Susan A., et al.
Publicado: (2020)

New Candidate Biomarkers in the Female Genital Tract to Evaluate Microbicide Toxicity
por: Fields, Scott, et al.
Publicado: (2014)

New developments in anti-malarial target candidate and product profiles
por: Burrows, Jeremy N., et al.
Publicado: (2017)

Identification of Selective Inhibitors of the Plasmodium falciparum Hexose Transporter PfHT by Screening Focused Libraries of Anti-Malarial Compounds
por: Ortiz, Diana, et al.
Publicado: (2015)

Gene Expression Analysis Reveals New Possible Mechanisms of Vancomycin-Induced Nephrotoxicity and Identifies Gene Markers Candidates
por: Dieterich, Christine, et al.
Publicado: (2009)

Erratum to: New developments in anti-malarial target candidate and product profiles
por: Burrows, Jeremy N., et al.
Publicado: (2017)

Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice
por: SheelaNair, Arya, et al.
Publicado: (2022)

Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D
por: Zogota, Rimants, et al.
Publicado: (2019)

Is "Malarial Cachexia" Purely Malarial?
por: Rogers, Leonard
Publicado: (1902)

Malarial Fevers and Malarial Parasites
Publicado: (1903)

Fake anti-malarials: start with the facts
por: Kaur, Harparkash, et al.
Publicado: (2016)

Potent in vivo anti-malarial activity and representative snapshot pharmacokinetic evaluation of artemisinin-quinoline hybrids
por: Lombard, Marli C, et al.
Publicado: (2013)

Last Steps as a Trainee, First Steps as a Consultant Specialist
por: O’Loughlin, C.
Publicado: (2022)

Amino-Substituted 3-Aryl- and 3-Heteroarylquinolines as Potential Antileishmanial Agents
por: Hammill, Jared T., et al.
Publicado: (2021)

Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia
por: Jarusiewicz, Jamie A., et al.
Publicado: (2017)

CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss
por: Teitz, Tal, et al.
Publicado: (2018)

Profiling of the anti-malarial drug candidate SC83288 against artemisinins in Plasmodium falciparum
por: Duffey, Maëlle, et al.
Publicado: (2018)

Procalcitonin as a Candidate Biomarker for Malarial Infection and Severe Malaria: A Meta-Analysis
por: Mahittikorn, Aongart, et al.
Publicado: (2022)

Predictors of past-year e-cigarette use among young adults
por: Struik, Laura L., et al.
Publicado: (2022)

Mediating role of body‐related shame and guilt in the relationship between weight perceptions and lifestyle behaviours
por: Lucibello, K. M., et al.
Publicado: (2020)

Acute Malarial Toxæmia, and the Pathology of Diseases of Malarial Origin
Publicado: (1870)

Body image emotions, perceptions, and cognitions distinguish physically active and inactive smokers
por: Contreras, Gisèle A., et al.
Publicado: (2015)

A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission
por: Baker, David A., et al.
Publicado: (2017)

Potent inhibitors of malarial P. Falciparum protein kinase G: Improving the cell activity of a series of imidazopyridines
por: Large, Jonathan M., et al.
Publicado: (2019)

MALARIAL PARASITOLOGY
por: Ewing, James
Publicado: (1901)

Malarial Fevers
por: O'Connell, M. D.
Publicado: (1891)

Malarial Fevers
por: Hall, G. C., et al.
Publicado: (1891)

Malarial Analogies
por: Roberts, J. R.
Publicado: (1891)

Cannot write session to /tmp/vufind_sessions/sess_uhp0r17obm947c2nm4uioc1ds5